Tobira Therapeutics Inc. (NASDAQ:TBRA) major shareholder Pentwater Capital Management L acquired 1,624,200 shares of the firm’s stock in a transaction on Thursday, September 22nd. The shares were bought at an average cost of $39.04 per share, for a total transaction of $63,408,768.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Pentwater Capital Management L also recently made the following trade(s):
- On Friday, September 23rd, Pentwater Capital Management L acquired 100,000 shares of Tobira Therapeutics stock. The shares were bought at an average cost of $39.19 per share, for a total transaction of $3,919,000.00.
Tobira Therapeutics Inc. (NASDAQ:TBRA) opened at 39.95 on Wednesday. Tobira Therapeutics Inc. has a 52 week low of $3.76 and a 52 week high of $41.39. The company’s market cap is $751.90 million. The stock has a 50 day moving average of $10.65 and a 200 day moving average of $9.40.
Tobira Therapeutics (NASDAQ:TBRA) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. The company earned $1.06 million during the quarter. Equities research analysts predict that Tobira Therapeutics Inc. will post ($2.65) earnings per share for the current fiscal year.
A number of equities research analysts have commented on the stock. Mizuho reissued a “buy” rating and set a $305.00 price objective on shares of Tobira Therapeutics in a report on Thursday, September 22nd. Cantor Fitzgerald lowered shares of Tobira Therapeutics from a “buy” rating to a “hold” rating and increased their price objective for the stock from $19.00 to $42.00 in a report on Wednesday, September 21st. HC Wainwright reissued a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Zacks Investment Research raised shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Wednesday, July 13th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $11.00 target price on shares of Tobira Therapeutics in a research note on Wednesday, August 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $68.63.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. bought a new position in Tobira Therapeutics during the second quarter worth approximately $177,000. BB Biotech AG bought a new position in Tobira Therapeutics during the second quarter worth approximately $5,878,000. State Street Corp increased its position in Tobira Therapeutics by 155.5% in the second quarter. State Street Corp now owns 109,527 shares of the biopharmaceutical company’s stock worth $1,377,000 after buying an additional 66,652 shares during the period. Teachers Advisors Inc. increased its position in Tobira Therapeutics by 287.1% in the second quarter. Teachers Advisors Inc. now owns 14,484 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 10,742 shares during the period. Finally, TFS Capital LLC bought a new position in Tobira Therapeutics during the second quarter worth approximately $533,000. 62.02% of the stock is owned by institutional investors and hedge funds.
Tobira Therapeutics Company Profile
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.